Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is modest, once again. We plan to hang with a short person or two, promenade the spirited official mascot and spend some time in front of the telly. And what about you? This remains a fine time to enjoy the great outdoors. You could stock up on turkey since the holiday is nearing or sound an alarm if you stumble across evidence of election fraud. Perhaps you might reach out to someone feeling isolated. Well, whatever you do, have a grand time. But be safe —wear a mask. Enjoy, and see you soon. …

Pfizer (PFE) and BioNTech (BNTX) plan to apply Friday to the Food and Drug Administration for an emergency use authorization for their Covid-19 vaccine, a watershed moment in the effort to curb the global pandemic, STAT says. It is unclear how long the FDA will take to review the application, though the agency is expected to move swiftly. The FDA pledged to seek advice from an expert panel of outside experts before ruling on the application, and panel members have been asked to hold three days in December as potential meeting dates.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.